Formed in 2022 when Ashfield and Huntsworth came together, Inizio is a market-leading health and life sciences partner with over 10,500 experts operating in more than 50 countries. We serve all of the world's top 20 pharma companies — and hundreds more beyond — connecting data, technology, and AI with expert human insight to simplify the complex, unlock value, and realize every product's potential across the full commercialization lifecycle.

We're a global community of scientists, strategists, medical communicators, marketers, and engagement specialists united by a single mission: getting life-changing products to patients faster. Across five specialized business units — Inizio Ignite, Inizio Medical, Inizio Evoke, Inizio Engage, and Inizio Biotech — we bring multidisciplinary human expertise and AI innovation to every stage of the journey, from earliest discovery to loss of exclusivity.

We support health and life sciences clients at every critical stage of the product lifecycle. Whether it's navigating clinical development, planning and executing a product launch, building commercialization strategy, deploying omnichannel engagement, or producing world-class congress experiences, we start with the challenge our clients face and create tailored, tech-empowered solutions that deliver measurable impact. Our Intelligent Commercialization™ approach connects human insight with data, AI, and proprietary platforms to accelerate smarter, faster decisions.

At Inizio, everything we do is in service of a single purpose: to empower health and life sciences companies to transform patients' lives. We believe that faster, smarter commercialization isn't just good business — it's how the world's most important medicines reach the people who need them most.

We are guided by our Code and Commitments — a set of shared behaviors that foster a positive, supportive, and ethical culture. We champion inclusion and impact, placing equity and belonging at the center of how we lead and deliver. We operate with rigorous governance in regulatory, IP, security, and compliance. And we measure ourselves by the outcomes we create — for our clients, our communities, and patients around the world.

With unmatched scale and scientific depth, Inizio is the only partner that connects strategy, medical affairs, marketing, commercial engagement, and biotech capabilities through a single, integrated model. We bring decades of industry experience, proprietary benchmarking data, award-winning AI platforms, and a global footprint of 10,500+ experts in 50+ countries. We're trusted by 100% of the world's top 20 pharma companies — not because we offer everything, but because we deliver exactly what's needed, every step of the way.

Sustainability at Inizio means minimizing environmental impact, championing inclusion, promoting health equity, and operating responsibly. We are committed to reaching Net Zero greenhouse gas emissions by 2040, with science-based targets to reduce Scope 1 & 2 emissions by 46.2% and Scope 3 by 27.5% by 2031. We've published a climate transition plan and annual sustainability reports, and are recognized by CDP, EcoVadis, Science Based Targets initiative, and the UN Global Compact for our progress.

Our impact extends beyond our clients. Through volunteer programs, charitable donations, and community action, our people use Inizio's scale to create meaningful and lasting change in the communities we serve. We elevate under-represented voices, support health equity initiatives, and work to improve diverse representation in clinical trials — because good science is inclusive science.

At Inizio, inclusion and impact aren't add-ons — they're how we work. We're pioneering a more inclusive future through our Inclusion & Impact framework, embedding practical behaviors into our shared systems and ways of working. With 30+ Business Employee Resource Groups (BERGs) and I&I Councils, inclusive leadership development, and allyship learning, we build a culture where everyone has access to opportunity. We also help clients embed inclusion into science, communications, and clinical strategy. Recognized as a 2025 OnCon Top 100 DEI Team Finalist and on the 2025 We Make Change Top 100 ChangeLeaders list.